benralizumab

This page shows the latest benralizumab news and features for those working in and with pharma, biotech and healthcare.

AZ expects return to growth this year after 2017 decline

AZ brought five new medicines to market in 2017 - including new cancer medicines Imfinzi (durvalumab) and Calquence (acalabrutinib) as well as Fasenra (benralizumab) for asthma - and added new indications for Lynparza

Latest news

AZ gets EMA green light for severe asthma drug Fasenra

Fasenra (benralizumab) is the third IL-5-targetting drug approved for market after GlaxoSmithKline’s Nucala (mepolizumab) and Teva’s Cinqaero (reslizumab) and according to AZ, it is the first biologic
GSK gets another approval for Nucala in US

which include AstraZeneca with recently approved Fasenra (benralizumab) and Teva’s Cinqair/Cinqaero (reslizumab).
EMA approves GSK’s triple COPD therapy

As with the triple, GSK is facing off against AZ in this category as the latter’s Fasenra (benralizumab) IL-5 blocker - recently approved by the FDA - is also in testing
AZ prices severe asthma drug Fasenra below competition

It’s the first approval for Fasenra (benralizumab), as well as the first for AZ’s emerging portfolio of respiratory biologic drugs, and the company says it is taking the marketing ... The FDA approval is based on the SIROCCO, CALIMA and ZONDA,
AZ severe asthma drug benralizumab backed by CHMP

AZ severe asthma drug benralizumab backed by CHMP. The IL-5 inhibitor set for European approval to treat severe eosinophilic asthma. ... benralizumab is “the first respiratory biologic with an eight-week maintenance dosing schedule”.

More from news
Approximately 8 fully matching, plus 25 partially matching documents found.

Latest Intelligence

Deal Watch March 2017

In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD)
Pharma deals in July 2015

In Japan, AZ paid $45m for an option with Kyowa Hakko Kirin to commercialise benralizumab (currently in phase III for treatment of severe uncontrolled asthma and COPD) in Japan.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Senior Programme Executive: Salary TBC

Senior Account Manager – Med Comms – Kent: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Senior Medical Writer: Great salary and bebefits

Senior Account Manager / Account Director: Great salary and bebefits

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Medical Writer: Great salary and benefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

Editor – Medical Education Agency – Bucks: Salary TBC

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Senior Account Manager or AD - Medical Communications: Salary TBC

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Account Manager – Med Comms – London: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Editorial Director – Medical Education – Oxford: Negotiable

Scientific Director: Great salary and bebefits

Subscribe to our email news alerts

PMHub

Add my company

Porterhouse Medical Group

Porterhouse Medical provides medical and scientific communication services to the pharmaceutical industry across the globe, with a focus on solutions...

Latest intelligence

No incentive for a cure: The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...